Lopez Karpovitch JX, Niesvizky R, et al: Comparison of colony-stimulating activities for evaluating in vitro granulo-monopoiesis in normal subjects and in patients with myeloid leukemia. Rev Invest Clin (Mex) 37:323, 1985

Ladanyi M, Feiner H, Niesvizky R, Michaeli J: Proto-oncogene analysis in multiple myeloma. Am J Pathol 141:949, 1992.

Niesvizky R, Siegel D, Michaeli J: 2-Chlorodeoxyadenosine for multiple myeloma.
Blood 81:868, 1993.

Niesvizky R, Calandri C, Patel ND, Xao SL, Potter BJ, Rand JH: Von Willebrand Factor binding to collagen in end stage renal disease patients. J Lab Clin Med 123:137-42, 1994.

Niesvizky R, Siegel D, Busquets X, Nichols G, Muindi J, Warrell RP, Michaeli J: Hypercalcemia and increased serum interleukin-6 levels induced by all-transretinoic acid in patients with multiple myeloma. Brit J Haematol 89:217-218, 1995.

Michaeli J, Niesvizky R, Siegel D, Ladanyi M, Lieberman P, Filippa D: Proteinaceous (Angiocentric Sclerosing) lymphadenopathy: A polyclonal systemic, non-amyloid deposition disorder. Blood 83:1159-1162, 1995

Bowne W, Lewis J, Filippa D, Niesvizky R, Brooks A, Burt M, Brennan M: The management of regional and multicentric Castleman's Disease. Cancer 85(3):706-17, 1999.

Niesvizky R, Louie D, Zhu A, Michaeli J: EBV-lymphoma after cladribine treatment for Waldenstrom's macroglobulinemia. (letter). New Eng J Med 341(1):55, 1999 Jul 1.

Zhu A., Niesvizky R, Filipa D, Hedrick E, Fata F, Filippa D, and Michaeli J: Extensive bone marrow necrosis associated with multiple myeloma (letter). Leukemia. 13 (12): 2118-20, 1999 Dec.

Niesvizky R, Siegel D, Glassman J, Straus D, Fine J, Lyons L and Michaeli J: Impact of Early Response to sequential high dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Leukemia and Lymphoma, 2002, 43 (3), 607-612

Niesvizky R, Choy CG and Michaeli J: Extended Survival in Advanced Stage Multiple Myeloma Patients Treated with Gallium Nitrate. Leukemia and Lymphoma, 2002, 43 (3), 603-605

Niesvizky R, Siegel D, Michaeli J: Biology and treatment of multiple myeloma. Blood Reviews 7:24-33, 1993.

Schuller D, Niesvizky R. Clinical Simulations in the Management of Herpes Virus Infection in the Immunocompromised Cancer Patient. Norwalk, CT: Medical Age Publishing 1994

Choy GC, Niesvizky R, Michaeli J: Multiple myeloma-Treatment Recommendations. Clin Immunother, 4:346-360, 1995.

Niesvizky, R, Warrell RP: Pathophysiology and management of bone disease in multiple myeloma. Cancer Invest, 15:85-90, 1997.

Niesvizky, R: Dr Joseph (Yosi) Michaeli, New York, USA. Obituary. Leukemia and Lymphoma, 2002, 43 (3), 683-684

Niesvizky, R: Gallium Nitrate in Multiple Myeloma: Prolonged Survival in a Cohort of Patients With Advanced-Stage Disease, Seminars in Oncology. 30(2 Suppl 5):20-4, 2003 Apr.

Niesvizky R , Martinez Banos Deborah M: Nuevas Alternativas Terapeuticas en Mieloma Multiple. In Mieloma Multiple, Eds. Jorge Vela Ojeda, et al. Ed. Elsevier, ISBN 970-9793-12-8, 2006

Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R and Michaeli J: BLTD (Clarithromycin (Biaxin), Low dose Thalidomide and Dexamethasone) for the treatment of myeloma and Waldenstrom?s Macroglobulinemia. Leukemia and Lymphoma, 2002, 43(9) pp 1777-1782

Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom?s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol.2003 Apr; 30(2):270-4.

Lane JM, Hong R., Koob J, Kiechle T., Niesvizky R, Pearse R, Siegel D, Poynton AR: Kyphoplasty enhances function and structural alignment in multiple myeloma. Clinical Orthropedics and Related Research, September 2004;(426):49-53.

Jagannath S. Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC. A Phase II Study of Two Doses of Bortezomib in relapsed or Refractory Myeloma. Br J Haematol 2004 Oct;127(2):165-72

Loic Vincent, David K Jin, Kofi Shido, Matthias A. Karajannis, Kathryn Walsh, Andrea T. Hooper, Ruben Niesvizky, Shahin Rafii. Fetal stromal-dependent paracrine and intracrine VEGF-A/VEGFR-1 signaling promotes proliferation and mortality of human primary myeloma cells. Cancer Res. 2005 Apr 15;65(8):3185-92

Achin A Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao-Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd Old, Hearn Jay Cho. The Cancer Testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma cell proliferation Blood. 2005 Jul 1;106(1):167-74. 2005 Mar 10.

John P. Leonard, Morton Coleman, Jamie Ketas, Michelle Ashe, Jennifer Fiore, Richard Furman, Ruben Niesvizky, Tsiporah Shore, Amy Chadburn, Heather Horne, Jacqueline Kovacs, Cliff Ding, William Wegener, Ivan Horak, and David Goldenberg. Combination antibody therapy with epratuzumab (humanized anti-CD22 antibody) and rituzimad (chimeric anti-CD20 antibody in relapsed/refractory non-Hodgkins lymphoma (NHL), J Clin Oncol. 2005 Jun 13

Scott Ely, Maurizio Di Liberto, Ruben Niesvizky, Linda B. Baughn, Hearn J. Cho, Eunice N. Hatada, Daniel M. Knowles, Joseph Lane and Selina Chen-Kiang. Mutually exclusive Cdk-4-Cyclin D1 and Cdk6-Cyclin D2 pairing inactivates Rb and promotes cell cycle dysregulation in multiple myeloma cells. Cancer Res. 2005 Dec 15;65(24):11345-53

James R. Berenson, Sundar Jagannath, Bart Barlogie, David T. Siegel, Raymond Alexanian, Paul G. Richardson, David Irwin, Melissa Alsina, S. Vincent Rajkumar, Gordon Srkalovic, Seema Singhal, Steven Limentani, Ruben Niesvizky, Dixie L. Esseltine, Elizabeth Trehu, David P. Schenkein, Kenneth Anderson.. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005 Nov 15;104(10):2141-8.

Alan D. Dosik, Morton Coleman, Lale Kostakoglu, Richard R. Furman, Jennifer M. Fiore, Daniel Muss, Ruben Niesvizky, Tsiporah Shore, Michael W. Schuster, Patricia Stewart, Shankar Vallabhajosula, Stanley J. Goldsmith, John P. Leonard. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma Cancer 2006 Feb 1;106(3):616-22

Linda B. Baughn, Maurizio Di Liberto, Kaida Wu, Peter L. Toogood, Tracey Louie, Rachel Gottschalk, Ruben Niesvizky, Hearn Cho, Scott Ely, Malcolm A.S. Moore and Selina Chen-Kiang. A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6 . Cancer Research 66, 7661-7667, August 1, 2006

Ruben Niesvizky, Tara Naib, Paul Christos, David Jayabalan, Jessica R. Furst, Jessica Jalbrzikowski, Faiza Zafar, Tomer Mark, Richard Lent, Roger Pearse, Scott Ely, John Leonard, Madhu Mazumdar, Selina Chen-Kiang and Morton Coleman Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment na•ve patients undergoing front-line lenalidomide and dexamethasone therapy. British Journal of Haematology, 138, 640?643, 2007

Ruben Niesvizky, DŽborah M. Mart’nez-Ba–os, Maria T. De Sancho, Madhu Mazumdar, Jessica R. Furst, John P. Leonard, David S. Jayabalan, Morton Coleman. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Submitted Leukemia Lymphoma, revisions requested

Ruben Niesvizky, David S. Jayabalan, Jessica R. Furst, Paul J. Christos, Hearn J. Cho, Roger N. Pearse, Faiza Zafar, Karen Pekle, Richard Lent, Scott Ely, David K. Jin, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael Schuster, Susan Mathew, John P. Leonard, Selina Chen-Kiang, Madhu Mazumdar, Morton Coleman. BiRD (Biaxin¨[clarithromycin]/Revlimid¨[lenalinomide]/Dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Na•ve Symptomatic Multiple Myeloma Patients. Submitted to Blood, Revisions requested

Donna M. Weber, Christine Chen, Ruben Niesvizky, Michael Wang, Andrew Belch, Edward Stadtmauer, David Siegel, Ivan Borrello, S. Vincent Rajkumar, Asher Alban Chanan-Khan, Sagar Lonial, John Patin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight. Randomized, Phase III, Placebo-Controlled Trial of Lenalidomide in Combination With High-Dose Dexamethasone for Relapsed or Primary Refractory Multiple Myeloma Submitted to New England Journal of Medicine, Revisions requested

Asher Alban Chanan-Khan, Ruben Niesvizky, Raymond J. Hohl, Todd M. Zimmerman, Neal P. Christiansen, Gary J. Schiller, Natalie Callander, John Lister, Martin Oken, Sundar Jagannath. Randomized Phase III Study of Dexamethasone With or Without Oblimersen Sodium (G3139; Bcl-2 Antisense) for Patients with Advanced Multiple Myeloma. Submitted

David Jayabalan*, Tomer Mark*, Richard Lent, Ethel Cesarman, Scott Ely, Roger Pearse, John Leonard, Morton Coleman, Selina Chen-Kiang, Ruben Niesvizky. Emerging New Electrophoretic Bands with Immunoglobulin Isotype Conversion in Multiple Myeloma Patients Treated with Lenalidomide. In Preparation

Ruben Niesvizky, Tomer Mark, David Jayabalan, Paul Christos, Richard Lent, Roger Pearse, Scott Ely, John Leonard, Tsiporah Shore, John Harpel, Michael Schuster, Madhu Mazumdar, Selina Chen-Kiang, Morton Coleman. The role of clarithromycin as a modulator of corticosteroid based therapy in myeloma. In Preparation

Ruben Niesvizky, Scott Ely, Maurizio DiLiberto, David S Jayabalan, Sangeeta Aggarwal, Janice L Gabrilove, Roger N Pearse, Faiza Zafar, Zoe Goldberg, John P Leonard, John J Wright, Morton Coleman, Selina Chen-Kiang. Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM). In Preparation